MedTrace Logo

Protocol for the Treatment of Metastatic Ewing Sarcoma

NCT02727387 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 155

Last updated 2022-09-19

No results posted yet for this study

Summary

Study for the treatment of metastatic Ewing sarcoma with high doses chemotherapy, radiotherapy and maintenance therapy.

Conditions

  • Ewing's Sarcoma (ES)

Interventions

DRUG

TEMIRI

Window therapy frontline for VHR patients

DRUG

ADM

Drug used in the Induction phase in association with Vincristine, Ifosfamide, cyclophosphamide and Etoposide

DRUG

IFO

Drug used in the Induction phase in association with Vincristine, Adriamycin, cyclophosphamide and Etoposide

DRUG

CYC

Drug used in the Induction phase in association with Vincristine, Ifosfamide, Adriamycin and Etoposide

DRUG

ETO

Drug used in the Induction phase in association with Vincristine, Ifosfamide, cyclophosphamide and Adriamycin

DRUG

BUMEL

Consolidation phase

DRUG

VIN

Drug used in the Induction phase in association with cyclophosphamide , Ifosfamide, Adriamycin and Etoposide

Sponsors & Collaborators

  • Italian Sarcoma Group

    lead NETWORK

Principal Investigators

  • Roberto Luksch, MD · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-01
Primary Completion
2022-04-29
Completion
2022-04-29

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02727387 on ClinicalTrials.gov